Ductal Carcinoma in Situ of the Breast
July 2023 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.

1:Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.
Authors:O'Shea AE, Clifton GT, Qiao N, Heckman-Stoddard BM, Wojtowicz M, Dimond E, Bedrosian I, Weber D, Garber JE, Husband A, Pastorello R, Lee JJ, Hernandez M, Liu DD, Vornik LA, Brown PH, Alatrash G, Peoples GE, Mittendorf EA
Institution:Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, Texas.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
Journal:Cancer Prev Res (Phila). 2023 Jun 1;16(6):333-341. doi: 10.1158/1940-6207.CAPR-22-0388.

2:Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
Authors:Laws A, Punglia RS
Institution:Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.
Journal:J Clin Oncol. 2023 Jun 10;41(17):3092-3099. doi: 10.1200/JCO.23.00455. Epub 2023 May 1.

3:A low risk of recurrence after breast-conserving surgery for DCIS: A single-institution experience.
Authors:van Bekkum S, Drukker C, van Rosmalen J, Menke-Pluijmers MBE, Westenend PJ
Institution:Department of Surgery, Albert Schweitzer Hospital, Dordrecht the Netherlands.; Department of Pathology, Laboratory of Pathology, Dordrecht, the Netherlands. Electronic address: pwestenend@paldordrecht.nl.
Journal:Cancer Treat Res Commun. 2023;35:100706. doi: 10.1016/j.ctarc.2023.100706. Epub 2023 Apr 11.

4:The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment.
Authors:Nash AL, Hwang ES
Institution:Department of Surgery, Duke University Medical Center, Durham, NC, USA. amanda.nash@duke.edu.
Journal:Ann Surg Oncol. 2023 Jun;30(6):3206-3214. doi: 10.1245/s10434-023-13370-1. Epub 2023 Apr 6.

5:Surgical Treatments for Ductal Carcinoma In Situ (DCIS) in Elderly Patients.
Authors:Buonomo OC, Pellicciaro M, Materazzo M, Berardi S, Gigliotti PE, Caspi J, Meucci R, Perretta T, Portarena I, Dauri M, Pistolese CA, Vanni G
Institution:Breast Unit, Department of Surgical Science, PTV Policlinico Tor Vergata University, Rome, Italy.
Journal:Anticancer Res. 2023 Apr;43(4):1555-1562. doi: 10.21873/anticanres.16305.

6:DCIS: When is accelerated partial breast irradiation an option? A meta-analysis on outcomes and eligibility.
Authors:Chua VH, Chua JH, Aniceto CJ, Antonio JA, Harina MDH, Martinez KC
Institution:Department of Medical Education and Research, Chinese General Hospital and Medical Center, Philippines. Electronic address: vanneszachua.md@gmail.com.
Journal:Am J Surg. 2023 May;225(5):871-877. doi: 10.1016/j.amjsurg.2023.03.004. Epub 2023 Mar 7.

7:Outcomes and imaging features of microinvasive carcinoma and ductal carcinoma in situ: Matched cohort study.
Authors:Yoon GY, Choi WJ, Kim HH, Cha JH, Shin HJ, Chae EY
Institution:Department of Radiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, 38 Bangdong-gil, Sacheon-myeon, Gangneung-si, Gangwon-do 25440, Republic of Korea.; Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Journal:Clin Imaging. 2023 Apr;96:64-70. doi: 10.1016/j.clinimag.2023.01.004. Epub 2023 Jan 13.

8:Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency.
Authors:Sprague BL, Chen S, Miglioretti DL, Gard CC, Tice JA, Hubbard RA, Aiello Bowles EJ, Kaufman PA, Kerlikowske K
Institution:Office of Health Promotion Research, University of Vermont, Burlington.; Department of Medicine, University of California, San Francisco.
Journal:JAMA Netw Open. 2023 Feb 1;6(2):e230166. doi: 10.1001/jamanetworkopen.2023.0166.

9:Clinical Outcomes of Conservative Treatment for Low-Risk Ductal Carcinoma in Situ: A Systematic Review and Pooled Analysis.
Authors:Co M, Cheng KCK, Yeung YH, Lau KC, Qian Z, Wong CM, Wong BY, Sin ELK, Wong HYS, Ma CH
Institution:Center for Education and Training, Department of Surgery, University of Hong Kong, Hong Kong; Division of Breast Surgery, Queen Mary Hospital, Hong Kong. Electronic address: mcth@hku.hk.; Center for Education and Training, Department of Surgery, University of Hong Kong, Hong Kong.
Journal:Clin Oncol (R Coll Radiol). 2023 Apr;35(4):255-261. doi: 10.1016/j.clon.2023.01.019. Epub 2023 Feb 1.

10:Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study.
Authors:Niu N, Zhang Y, Bai Y, Wang X, Yan S, Song D, Xu H, Liu T, Hua B, Zhang Y, Liu J, Qiao X, Liu J, Zheng X, Cao H, Liu C
Institution:Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Journal:Elife. 2023 Feb 6;12:e83045. doi: 10.7554/eLife.83045.

11:Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial.
Authors:Strnad V, Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Łyczek J, Guinot JL, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Polat B, Fietkau R, Schlamann A, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Dunst J, Gall C, Uter W
Institution:Department of Radiation Oncology, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. Electronic address: vratislav.strnad@uk-erlangen.de.; Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Nuremberg, Germany.
Journal:Lancet Oncol. 2023 Mar;24(3):262-272. doi: 10.1016/S1470-2045(23)00018-9. Epub 2023 Feb 1.

12:Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ.
Authors:Byng D, Thomas SM, Rushing CN, Lynch T, McCarthy A, Francescatti AB, Frank ES, Partridge AH, Thompson AM, Retèl VP, van Harten WH, Grimm LJ, Hyslop T, Hwang ES, Ryser MD
Institution:From the Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands (D.B., V.P.R., W.H.v.H.); Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, the Netherlands (D.B., V.P.R., W.H.v.H.); Duke Cancer Institute Biostatistics Shared Resource (S.M.T., C.N.R., T.H.) and Department of Mathematics (M.D.R.), Duke University, Durham, NC; Department of Biostatistics and Bioinformatics (S.M.T., T.H.), Division of Surgical Sciences, Department of Surgery (T.L., E.S.H.), Department of Radiology (L.J.G.), and Department of Population Health Sciences (M.D.R.), Duke University Medical Center, 215 Morris St, Durham, NC 27701; Cancer Programs, American College of Surgeons, Chicago, Ill (A.M., A.B.F.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Mass (E.S.F., A.H.P.); and Department of Surgery, Baylor College of Medicine, Houston, Tex (A
Journal:Radiology. 2023 Apr;307(1):e221210. doi: 10.1148/radiol.221210. Epub 2023 Jan 10.

13:Is Sentinel Lymph Node Biopsy Necessary in Patients who Undergo Prophylactic Mastectomy?
Authors:Madan V, Mamounas EP
Institution:Johns Hopkins University, Baltimore, MD.; Orlando Health Cancer Institute, Orlando, FL. Electronic address: terry.mamounas@orlandohealth.com.
Journal:Clin Breast Cancer. 2023 Feb;23(2):231-236. doi: 10.1016/j.clbc.2022.12.003. Epub 2022 Dec 8.

14:Factors associated with ductal carcinoma in situ (DCIS) treatment patterns and patient-reported outcomes across a large integrated health network.
Authors:Kim H, Wang H, Demanelis K, Clump DA, Vargo JA, Keller A, Diego M, Gorantla V, Smith KJ, Rosenzweig MQ
Institution:Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. kimxhx2@upmc.edu.; Department of Nursing, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Journal:Breast Cancer Res Treat. 2023 Feb;197(3):683-692. doi: 10.1007/s10549-022-06831-w. Epub 2022 Dec 17.

15:Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women.
Authors:Skjerven HK, Myklebust EM, Korvald C, Porojnicu AC, Kaaresen R, Hofvind S, Schlicting E, Sahlberg KK
Institution:Section for Breast and Endocrine Surgery, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: Helle.skjerven@vestreviken.no.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway.
Journal:Eur J Surg Oncol. 2023 Mar;49(3):575-582. doi: 10.1016/j.ejso.2022.11.594. Epub 2022 Dec 1.

16:Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.
Authors:Udayasiri RI, Luo T, Gorringe KL, Fox SB
Institution:Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Journal:Histopathology. 2023 Jan;82(1):106-118. doi: 10.1111/his.14804.

17:Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence.
Authors:O'Keefe TJ, Chau H, Harismendy O, Wallace AM
Institution:Division of Breast Surgery and the Comprehensive Breast Health Center, University of California San Diego, La Jolla, CA. Electronic address: tokeefe@health.ucsd.edu.
Journal:Surgery. 2023 Feb;173(2):305-311. doi: 10.1016/j.surg.2022.10.009. Epub 2022 Nov 23.

18:Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.
Authors:Shiino S, Quinn C, Ball G, Syed BM, Kurozumi S, Tsuda H, Rakha EA
Institution:Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. emad.rakha@nottingham.ac.uk.
Journal:Breast Cancer Res Treat. 2023 Jan;197(2):245-254. doi: 10.1007/s10549-022-06800-3. Epub 2022 Nov 24.

19:A systematic review of oncological outcomes after nipple-sparing mastectomy for breast cancer.
Authors:Zaborowski AM, Roe S, Rothwell J, Evoy D, Geraghty J, McCartan D, Prichard RS
Institution:Department of Breast and Endocrine Surgery, St. Vincent's University Hospital, Elm Park, Dublin, Ireland.
Journal:J Surg Oncol. 2023 Mar;127(3):361-368. doi: 10.1002/jso.27115. Epub 2022 Oct 8.

20:The Effect of Lumpectomy and Cavity Shave Margin Status on Recurrence and Survival in Breast-Conserving Surgery.
Authors:Abdelsattar JM, Afridi FG, Dai Z, Yousaf N, Seldomridge A, Battin AO, Wen S, Gray D, Marsh JW, Cowher MS, Partin JF, Hazard-Jenkins H, Lupinacci K
Institution:Department of Surgery, 53422West Virginia University, Morgantown, WV, USA.
Journal:Am Surg. 2023 Mar;89(3):424-433. doi: 10.1177/00031348211030464. Epub 2021 Jul 1.

For a FREE PREVIEW of the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast...
at a Special 25% Discount

Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast

Updated: January 17, 2023
158 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $39.95
  • Less 25% Discount = - $10.00
  • Discounted Price = $29.95(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $26.60
  • Less 25% Discount = - $6.65
  • Discounted Price = $19.95

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 25% discount when you order your Guidebook by phone.

To receive your 25% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: January 5, 2024

What Our Customers Are Saying...

"The MediFocus Guidebook on DCIS was more than adequate for my research on this condition and I would recommend it to anyone wanting the "whole picture". Thank you for providing this excellent service."
Los Angeles, California

"At a very difficult time, your MediFocus Guidebook on Ductal Carcinoma in Situ helped our family make informed decisions. Thank you for your help!"
Metarie, Louisiana

"I was recently diagnosed with DCIS and was looking everywhere for information to get myself educated. The MediFocus Guidebook was very helpful in clarifying everything for me. The information is so well organized that it makes it easy to read and understand. I feel much better now that I've read this Guidebook and have a clearer understanding of the issues that I face. I highly recommend this Guidebook to anyone seeking to understand DCIS."
Ft. Lauderdale, Florida

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.